UBS Group’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$37.1M Sell
143,525
-16,070
-10% -$4.28M 0.01% 1940
2025
Q4
$39.3M Buy
159,595
+29,422
+23% +$6.19M 0.01% 1879
2025
Q3
$23M Buy
130,173
+32,933
+34% +$4.93M ﹤0.01% 2403
2025
Q2
$13.4M Buy
97,240
+16,121
+20% +$2.37M ﹤0.01% 2800
2025
Q1
$14.6M Sell
81,119
-19,012
-19% -$3.2M ﹤0.01% 2652
2024
Q4
$15.7M Buy
100,131
+63,802
+176% +$11.3M ﹤0.01% 2595
2024
Q3
$6.61M Buy
36,329
+7,773
+27% +$1.5M ﹤0.01% 2777
2024
Q2
$5.24M Sell
28,556
-22,472
-44% -$3.77M ﹤0.01% 2840
2024
Q1
$9.08M Buy
51,028
+20,268
+66% +$2.82M ﹤0.01% 2355
2023
Q4
$3.82M Buy
+30,760
New +$3.41M ﹤0.01% 3067
2023
Q3
Sell
-11,217
Closed -$1.32M 9734
2023
Q2
$1.32M Sell
11,217
-16,911
-60% -$1.73M ﹤0.01% 3974
2023
Q1
$2.25M Sell
28,128
-14,495
-34% -$1.14M ﹤0.01% 3292
2022
Q4
$3.38M Buy
42,623
+42,459
+25,890% +$3.15M ﹤0.01% 2860
2022
Q3
$11K Sell
164
-15,670
-99% -$1.13M ﹤0.01% 8304
2022
Q2
$1.04M Sell
15,834
-42,236
-73% -$2.63M ﹤0.01% 3711
2022
Q1
$3.86M Buy
58,070
+56,237
+3,068% +$3.51M ﹤0.01% 2789
2021
Q4
$128K Sell
1,833
-21,490
-92% -$1.25M ﹤0.01% 6075
2021
Q3
$1.22M Buy
23,323
+21,315
+1,062% +$1.26M ﹤0.01% 4015
2021
Q2
$137K Sell
2,008
-35,379
-95% -$2.47M ﹤0.01% 5629
2021
Q1
$2.88M Buy
37,387
+23,258
+165% +$1.69M ﹤0.01% 3186
2020
Q4
$848K Buy
14,129
+2,192
+18% +$109K ﹤0.01% 4150
2020
Q3
$514K Buy
11,937
+11,666
+4,305% +$507K ﹤0.01% 4173
2020
Q2
$11K Sell
271
-16,539
-98% -$796K ﹤0.01% 6948
2020
Q1
$727K Buy
16,810
+5,636
+50% +$295K ﹤0.01% 3637
2019
Q4
$619K Sell
11,174
-21,394
-66% -$1.05M ﹤0.01% 4645
2019
Q3
$1.13M Buy
32,568
+31,843
+4,392% +$1.42M ﹤0.01% 3861
2019
Q2
$29K Buy
+725
New +$23.7K ﹤0.01% 6357
2019
Q1
Sell
-675
Closed -$14K 7948
2018
Q4
$14K Buy
+675
New +$14.1K ﹤0.01% 7042
2017
Q4
Sell
-2,562
Closed -$26K 7979
2017
Q3
$26K Buy
+2,562
New +$25.8K ﹤0.01% 6269

Other funds holding KRYS